Stock CDTX CIDARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.5125 USD -0.27% Intraday chart for Cidara Therapeutics, Inc. -96.49% -96.77%
Apr. 23 Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket MT
Apr. 22 Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M MT

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Number of employees: 73

Sales per Business

USD in Million2021Weight2022Weight Delta
Antifungal and Antiviral Drugs
100.0 %
50 100.0 % 64 100.0 % +29.69%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
50 100.0 % 64 100.0 % +29.69%

Managers

Managers TitleAgeSince
Jeffrey Stein CEO
 Chief Executive Officer 69 13-12-31
Preetam Shah DFI
 Director of Finance/CFO 51 21-08-31
Les Tari CTO
 Chief Tech/Sci/R&D Officer 57 12-12-31
Taylor Sandison CTO
 Chief Tech/Sci/R&D Officer 52 15-09-30
Shane Ward COO
 Chief Operating Officer 49 21-08-31
Nicole Davarpanah PRN
 Corporate Officer/Principal - 23-08-15
Allison Lewis HRO
 Human Resources Officer - 15-01-31
Carmen Betancourt LAW
 General Counsel - 13-12-31
Laura A. Navalta PRN
 Corporate Officer/Principal - 17-09-30

Members of the board

Members of the board TitleAgeSince
Daniel Burgess CHM
 Chairman 62 14-03-31
Theodore Schroeder BRD
 Director/Board Member 69 14-03-31
Jeffrey Stein CEO
 Chief Executive Officer 69 13-12-31
Timothy Franson BRD
 Director/Board Member 72 15-02-28
David Gollaher BRD
 Director/Board Member 74 18-09-09
Chrysa Mineo BRD
 Director/Board Member 59 18-02-28
Bonnie Bassler BRD
 Director/Board Member 61 21-01-21
Carin Canale-Theakston BRD
 Director/Board Member 50 21-01-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 90,619,040 83,795,451 ( 92.47 %) 0 92.47 %

Shareholders

NameEquities%Valuation
BVF, Inc.
7.571 %
6,861,127 7.571 % 6 M $
Mundipharma International Ltd.
5.276 %
4,781,408 5.276 % 4 M $
Vanguard Global Advisers LLC
3.693 %
3,346,260 3.693 % 3 M $
Medical Strategy GmbH
3.287 %
2,978,246 3.287 % 3 M $
Apo Asset Management GmbH
2.166 %
1,962,656 2.166 % 2 M $
Renaissance Technologies LLC
1.989 %
1,802,173 1.989 % 2 M $
Alethea Capital Management LLC
1.796 %
1,627,670 1.796 % 1 M $
Nantahala Capital Management LLC
1.707 %
1,546,745 1.707 % 1 M $
Jeffrey Stein
1.685 %
1,527,304 1.685 % 1 M $
Point72 Asset Management LP
1.379 %
1,250,000 1.379 % 1 M $
NameEquities%Valuation
BVF Partners LP
42.72 %
241,440 42.72 % 222 125 $

Company contact information

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive Suite 101

92121, San Diego

+858 752 6170

http://www.cidara.com
address Cidara Therapeutics, Inc.(CDTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Cidara Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5139 USD
Average target price
90 USD
Spread / Average Target
+17,413.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CIDARA THERAPEUTICS, INC. Stock Cidara Therapeutics, Inc.
-96.77% 46.57M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 96.73B
ARGENX SE Stock argenx SE
+1.66% 21.31B
BIONTECH SE Stock BioNTech SE
-16.16% 21.21B
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CDTX Stock
  4. Company Cidara Therapeutics, Inc.